The central question is no longer whether we can innovate, but whether innovation can truly reach patients in time.
Nemvaleukin showed promising antitumor activity and manageable safety in advanced solid tumors, both alone and with pembrolizumab. ARTISTRY-1 study included dose-escalation, dose-expansion, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results